DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 28, 2006--Elan Corporation, plc today announced it has agreed with the Irish Stock Exchange (ISE), the Financial Services Authority in the United Kingdom and the New York Stock Exchange (NYSE) to suspend trading of its securities (ADRs and ordinary shares) during the scheduled U.S. Food and Drug Administration (FDA) Advisory Committee meeting to review Tysabri, commencing March 7, 2006, for up to two days.
